M. Blute

发表

Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer.

H. Zincke, M. Lieber, S. Lerner, 1995, Oncology.

Long-term follow-up of untreated stage T1a prostate cancer.

D. Bostwick, L. Cheng, R. Neumann, 1998, Journal of the National Cancer Institute.

Predictors of cancer progression in T1a prostate adenocarcinoma.

D. Bostwick, E. Bergstralh, L. Cheng, 1999, Cancer.

Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma.

D. Bostwick, M. Blute, H. Zincke, 1999, The Journal of urology.

Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results.

H. Zincke, R. Richardson, S. Lerner, 1995, Mayo Clinic proceedings.

Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.

E. Bergstralh, B. Leibovich, M. Blute, 2000, The Journal of urology.

Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.

C. Amling, H. Zincke, S. Bryant, 2000, Mayo Clinic proceedings.

Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.

D. Bostwick, A. Weaver, M. Blute, 2001, The Journal of urology.

Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.

M. Blute, H. Zincke, G. Farrow, 1991, The Journal of urology.

Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.

J. Oesterling, H. Lilja, H. Zincke, 1996, Urology.

Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.

D. Bostwick, M. Blute, A. Lopez‐Beltran, 1998, The Journal of urology.

Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney.

A. Weaver, M. Blute, H. Zincke, 2000, Mayo Clinic proceedings.

Nephron-sparing surgery and renal cell carcinoma.

B. Leibovich, H. Zincke, J. Routh, 2004, JAMA.

Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.

M. Blute, H. Zincke, M. Blute, 1998, The Journal of urology.

Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup.

D. Bostwick, K. Iczkowski, M. Blute, 1999, The Journal of urology.

Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.

D. Bostwick, M. Gettman, J. Slezak, 1999, Urology.

Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.

M. Blute, A. Grabner, P. Wollan, 1996, The Journal of urology.

Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.

E. Bergstralh, M. Blute, H. Zincke, 1996, The Journal of urology.

Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.

J. Oesterling, H. Zincke, G. Farrow, 1993, Urology.

Long-term followup of young patients with stage A adenocarcinoma of the prostate.

M. Blute, H. Zincke, G. Farrow, 1986, The Journal of urology.

Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

E. Bergstralh, M. Blute, H. Zincke, 2001, The Journal of urology.

Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

J. Oesterling, E. Bergstralh, M. Blute, 1994, The Journal of urology.

Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.

E. Bergstralh, M. Blute, C. Amling, 2000, The Journal of urology.

Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison.

E. Bergstralh, R. Ghavamian, M. Blute, 1999, The Journal of urology.

Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution.

J. Oesterling, E. Bergstralh, M. Blute, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.

D. Bostwick, E. Bergstralh, M. Blute, 1997, Urology.

Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.

D. Bostwick, E. Bergstralh, H. Zincke, 1996, The Journal of urology.

Stage pT1 conventional (clear cell) renal cell carcinmoa: pathological features associated with cancer specific survival.

J. Cheville, A. Weaver, C. Lohse, 2001, The Journal of urology.

Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review

J. Cheville, A. Weaver, C. Lohse, 2003, BJU international.

Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma.

D. Bostwick, M. Blute, H. Zincke, 1996, The Journal of urology.

Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.

M. Blute, H. Zincke, N. Itano, 2000, The Journal of urology.

Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity.

M. Blute, H. Zincke, S. Lerner, 1995, The Journal of urology.

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

E. Bergstralh, M. Blute, C. Amling, 2001, The Journal of urology.

Cancer volume of lymph node metastasis predicts progression in prostate cancer.

J. Cheville, D. Bostwick, E. Bergstralh, 1998, The American journal of surgical pathology.

Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis.

T. Therneau, M. Blute, O. Nativ, 1990, Archives of surgery.

Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract.

H. Zincke, R. Richardson, S. Lerner, 1996, Mayo Clinic proceedings.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

E. Bergstralh, M. Blute, H. Zincke, 2001, Mayo Clinic proceedings.

Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.

D W Hillman, J. Cheville, M. Blute, 2000, The Journal of urology.

Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.

H. Zincke, S. Lerner, M. Blute, 1995, The Journal of urology.

Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.

C. Amling, H. Zincke, E. Bergstralh, 1997, Seminars in Urologic Oncology.

Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.

D. Bostwick, C. Amling, H. Zincke, 1998, Mayo Clinic proceedings.

Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.

E. Bergstralh, R. Ghavamian, H. Zincke, 1999, Urology.

Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens.

D. Bostwick, J. Earle, T. Pisansky, 1996, International journal of radiation oncology, biology, physics.

Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.

J. Oesterling, E. Bergstralh, H. Zincke, 1993, Urology.

Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.

D. Bostwick, B. Leibovich, B. Davis, 2000, Urology.

Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.

J. Cheville, T. Pisansky, S. Schild, 2000, The Journal of urology.